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A B S T R A C T
Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deﬁciency of the
lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globo-
triaosylceramide (Gb3). Although the introduction of Enzyme Replacement Therapy (ERT) resulted in a variety
of clinical beneﬁts, life-long intravenous (IV) treatment with ERT with an every other week schedule, may
interfere with daily life activities and impact on QoL. We report here a multicentric, observational, longitudinal
data analysis on a large cohort of 85 Italian FD patients (45 males, 40 females) from 11 out of 20 Italian regions,
who received a cumulative number of 4269 home infusions of agalsidase alfa. For the whole cohort, the average
duration of home therapy was 1 year and 11 months (range 3 months–4 years and 6 months), and during this
period, compliance to treatment (number of infusions performed vs scheduled) reached 100%. The EQ-5 VAS
scale was administered to patients to evaluate the self-reported QoL, 58% of patients showing an increase of EQ-
5 VAS score at follow up compared to baseline (home treatment start) or remaining stable. A mild increase of
average disease severity, measured through Mainz Severity Score Index (MSSI), was found during hospital
treatment (p < 0,007), while it remained stable between the ﬁrst home therapy infusion and last follow up.
Interestingly, 4 out of 7 (57%) patients, showing an improvement in FD-related clinical status after starting home
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therapy, had previously a sub-optimal compliance to treatment during the period of hospital treatment man-
agement. Only 4 adverse non serious reactions (0,093%) were reported totally in 2 patients during home
treatment.
We conclude that home infusions in eligible patients with FD are safe, contribute to improve treatment
compliance and therapeutic clinical outcomes, and may have a positive impact on self-perceived QoL.
1. Introduction
Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage
disorder caused by a deﬁciency of the lysosomal enzyme alpha-ga-
lactosidase A [E.C.3.2.1.22], resulting in progressive accumulation of
globotriaosylceramide (Gb3) and related glycosphingolipids (galabio-
sylceramide) in lysosomes within tissues and organs throughout the
body. Reported incidence, ranging from 1 in 476,000 to 1 in 117,000
[1,2] in the general population, may underestimate the true prevalence:
newborn screening initiatives have found a prevalence of the disease as
high as 1 in ~3100 newborns in Italy [3]. Due to the X-linked in-
heritance, the disease primarily aﬀects males, but females can be af-
fected as well [4–7] and both sexes can display symptoms during
childhood [8–12]. The most frequent symptoms complained by pedia-
tric patients with FD are episodes of recurrent pain in hands and feet
(acroparesthesias), and gastrointestinal symptoms (mainly abdominal
pain and diarrhea), manifestations that interfere with child's well-being
and school performance and have a severe impact on quality of life
(QoL) [8,12,13]. With age, progressive damage to vital organ systems
develops in both genders [14], leading to multi-organ failure and even
more reducing QoL [13] although the clinical expression of the disease
has a wide inter- and intra-familial variability [15]. Additionally, end-
stage renal disease and life-threatening cardiovascular or cere-
brovascular complications limit life-expectancy [16,17].
The introduction of Enzyme Replacement Therapy (ERT), available
since 2001, as a speciﬁc therapeutic option for patients with FD, re-
sulted in a variety of clinical beneﬁts including improved renal pa-
thology and cardiac function, reduced severity of neuropathic pain and
improved pain-related QoL as well as signiﬁcantly improved life-ex-
pectancy [18,19]. In order to monitor disease progression and patients'
response to ERT, Mainz Severity Score Index (MSSI) has been developed
as a clinical scoring-system speciﬁc for FD, which reﬂects disease's se-
verity and it has been validated as a sensitive tool to allow monitoring
treatment response in individual patients [22].
Despite the encouraging clinical outcomes achieved with ERT, a life-
long intravenous (IV) treatment with an every other week schedule,
may interfere with daily life activities and negatively impact on QoL.
The availability of a home treatment option for patients with FD, re-
sulted in a safe and practicable way to improve patient experience and
reduced the “burden of treatment”. In addition, home treatment is as-
sociated with improved adherence to treatment and with a signiﬁcant
and positive impact on QoL [20,21].
On the basis of our ﬁve year experience with home treatment for FD,
we ﬁrst aimed at assessing the impact of home therapy with agalsidase
alfa on improvement in QoL in a large cohort of Italian patients with
FD, in comparison with standard hospital-based ERT. The second ob-
jective was to evaluate if the beneﬁt of home therapy could positively
inﬂuence the clinical progression of FD as calculated by MSSI, and if
higher levels of compliance with home-treatment than hospital-based
ERT could contribute to the stabilization in MSSI score, thus reﬂecting
an additional positive eﬀect on the progression of the disease.
2. Patients and methods
2.1. Fabry@Home program
The Home Therapy program, called Fabry@Home, involves a pro-
fessional team consisting of a treating physician and a registered nurse.
The nurse visits patients with FD every 2 weeks to perform the infusion
of agalsidase alfa at the in-label dosage of 0,2 mg/kg in 40 min, ac-
cording to drug indication and SmPc. The nurse is responsible for
checking drug vial condition before administration, recording details of
administered vials (number of vials and batch numbers), controlling for
vital signs before and after administration and any adverse reactions
during and after infusions. The nurse remains at the patient's side until
the infusion is completed and post-infusion vital signs are recorded. The
nurse dedicated to the infusion of agalsidase alfa is in real-time remote
contact with the physician of the team who is immediately notiﬁed in
case of an adverse event. This is in order to warrant that any adverse
event during the infusion is timely and properly addressed. Patients
who underwent any adverse reaction have been subsequently evaluated
for a premedication treatment with antihistaminics and/or corticos-
teroids before the following infusions, in accordance with the treating
physician of the Fabry clinic who is charge of periodically following the
patient up in order to monitor the progression of disease, response to
treatment and safety.
To be eligible to enter the Home Therapy program, each patient is
required to fulﬁll the following criteria:
- At least eight ERT infusions for FD, at least three of which with
agalsidase alfa, at his local Fabry clinic or infusion center;
- -Stable clinical conditions (no deteriorating target organ damage,
i.e. renal, cardiovascular, cerebrovascular damage);
- No evidence of adverse reactions to ERT reported during the last
four infusions.
- Each patient has to sign an informed consent before joining the
home infusion program.
2.2. Patients and data collection
Patients with FD who have been treated with agalsidase alfa in the
home therapy program for a period of at least 3 months were enrolled
in the study. June 2013 has been chosen as a cut oﬀ time for the data
collection and analysis.
All patients enrolled in the study gave informed consent and the
study was approved by the local Ethical Committee.
In order to evaluate the self-reported QoL and health-related status,
the EQ visual analogue scale (VAS) of the EQ-5 questionnaire was ad-
ministered to each patient at the time of entering the home therapy
program (before the ﬁrst home infusion) and prospectively at the last
follow up during the home treatment. The EQ VAS records the re-
spondent's self-rated health on a vertical, visual analogue scale where
the endpoints are labelled “Best imaginable health state” (100) and
“Worst imaginable health state” (0). This information can be used as a
quantitative measure of health outcome as judged by the individual
respondents.
In addition, on the basis of the information contained in medical
records, MSSI was retrospectively calculated for each patient at the
time of the diagnosis, at the time of entering the home therapy program
and at the last follow up with the aim of assessing clinical conditions
and response to treatment. MSSI was published in 2004 for use in pa-
tients with Fabry disease [22] and is composed of four sections that
cover the general, neurological, cardiovascular and renal signs and
symptoms of FD. Each section includes a group of signs and symptoms
that are associated with FD, and these are weighted according to their
contribution to the morbidity of the disease. MSSI was associated to a
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mild disease severity for values between 0 and 20, moderate for values
between 20 and 40, and severe for values higher than 40.
Finally, adherence to the infusion schedule during the previous
12 months and the number of requests for leaving the home therapy
program raised by patients or treating physicians were assessed as in-
direct eﬀectiveness indicators of home infusion program. Adherence to
treatment was calculated considering a compliance of 95–100% for
those patients who missed 0 to 1 infusions, 90–95% for those who
missed 2 infusions, 80–90% for those who missed from 3 to 5 infu-
sions,< 80% for those who missed> 5 infusions compared to the
previous year before entering the home therapy program. Data on ad-
herence to treatment during home therapy were compared with those
observed during the last six months of hospital treatment, as reported
by treating physicians or self-reported by patients at the time of en-
tering the home treatment program. As safety indicators, the number of
adverse events reported during the home treatment were considered
and compared with that observed during the hospital treatment.
2.3. Statistical analysis
Descriptive statistical analysis was applied. For comparisons, non-
parametric tests (Wilcoxon two-sample test, Friedman test) were used
as appropriate. p < 0,05 was considered signiﬁcant.
3. Results
Each patient evaluated in the study was home treated for a period of
at least 3 months. These 85 patients represent the 35% of the total
number of patients treated in Italy with agalsidase alfa at the time of the
analysis and originally came from 21 Fabry Clinics across Italy. This
cohort was composed of 45 males (53%; mean age: 40.6 years; range
12–69 years) and 40 females (47%; mean age: 48,8 years; range
17–74 years). Five patients (5,8%) entered the home treatment pro-
gram before the age of 18 (mean 13,6 years; range: 10–16 years).
Patients who were enrolled in the home treatment program had started
ERT 4 years before (average treatment duration; range 4 months–11 -
years and 6 months). Seventeen out of 85 patients (20%) started ERT
with agalsidase beta and then were switched to agalsidase alfa ac-
cording to standard clinical practice and treating physician decision
without undergoing adverse events. For the whole cohort, the average
duration of home treatment was 1 year and 11 months (range
3 months–4 years and 6 months). Ten out of 85 patients (11,7%)
abandoned the home treatment program after at least 3 months due to
the following reasons: death for incoming acute cardiac complications
(3 patients), treating physician decision (4 patients), bureaucratic and
administrative issues due to the decision of one Italian region to
withdraw the consent for the home patients (2 patients). No patient
asked to leave the home treatment program except one showing psy-
chiatric disturbances. The cohort of FD patients treated at home within
the program included also 2 pregnant women. One female patient and
four male patients underwent kidney transplantation before the be-
ginning of home therapy. A total of 4269 infusions (mean: 50 infusions/
patient; range: 7–118) was performed for the whole cohort during the
observation. Seventy-four out of 85 patients (87%) were treated by the
same nurse during the whole period of home treatment, while 11 out 85
patients (13%) have been infused by more than one nurse during the
observation. The home infusion program was available in 11 out of 20
Italian regions (55%). In Table 1 clinical baseline characteristics of the
85 patients are reported.
3.1. EQ-5 VAS
To evaluate the self-reported QoL and health related status, the EQ-
5 VAS was administered to patients enrolled in the study immediately
before initiating home therapy and at last follow up. Complete data
regarding EQ-5 VAS was available for 72 out of 85 patients (85%)
(initial and follow up data missing for 1 and 12 patients, respectively).
We found no statistically signiﬁcant diﬀerence regarding average self-
reported health-related status between pre home treatment and the last
follow up (mean: 70). However, among all 72 patients, 42 (58%)
showed an increase of EQ-5 VAS score at follow up compared to
baseline (before starting home infusions), reﬂecting an improvement of
health status, or remained stable (20 and 22, respectively). On the
contrary 30 patients (42%) reported a worsening of their health-related
status. In the group of patients who experienced an improvement of EQ-
5 VAS (20 patients) the average of EQ5-VAS increased of 21,5. In ad-
dition, EQ-5 VAS score ranged between 20 and 100 at baseline and
between 60 and 100 at follow up, thus standing for an increase of self-
reported health-related status after home therapy start in patients with
lower score at baseline. This is conﬁrmed by the calculation of the in-
terquartile range (IQR) which showed two overlapping values (=20) in
the two groups (EQ5-VAS at baseline vs EQ5-VAS at follow up) in-
dicating a homogeneous dispersion of the values. No diﬀerences re-
garding gender and age at treatment initiation have been observed.
3.2. Mainz Severity Score Index (MSSI)
MSSI was calculated at three time points: the time of diagnosis,
immediately before starting home therapy and at last follow up. MSSI
data was available at the time of diagnosis, at the time of starting home
therapy and at the last follow up for 73 (86%), 75 (88%), 74 (87%)
patients out of 85, respectively, being the other records lost. At the time
of diagnosis, MSSI ranged from 1 to 55 (mean 16,1, median 13,0); at the
time of entering the home therapy program it ranged from 2 to 56
(mean 18,6, median 16,0) while at last follow up it ranged between 2
and 54 (mean 19,3, median 16.0).
During the hospital treatment period occurring between diagnosis
and home therapy start, 10 out 73 patients (14%) showed a progression
of disease by switching from a mild to a moderate disease status or from
a moderate to a severe status. Only one patient showed a clinical status
amelioration while the remaining 63 patients (85%) showed no change
in disease severity according to MSSI. On the other end, after starting
the home therapy program, 10 out of 74 patients (14%) showed a
progression of disease, while 7 out of 74 patients (9%) registered an
improvement of clinical status related to FD by switching from a severe
to a moderate class or from a moderate to a mild class according to
MSSI. Fifty-seven out of 74 patients (77%) showed no progression of
disease and remained stable between starting home therapy and follow
up.
Interestingly, 4 out of 7 (57%) patients, showing an improvement in
FD-related clinical status after starting home therapy, had previously a
sub-optimal compliance to treatment during the period of hospital
treatment management (< 95%).
Generally, for all 74 patients, average disease severity as calculated
by MSSI showed a slight increase in the timeframe between the diag-
nosis and immediately before starting home therapy (p < 0,007) while
it remained stable between the ﬁrst home therapy infusion and last
follow up.
3.3. Safety and compliance to treatment
Compliance to treatment (number of infusions performed vs
scheduled) reached 100% in patients during the home therapy program
while during hospital management, compliance had been of 95–100%
for 44 patients, 90–95% for 13 patients, 80–90% for 4 patients and<
80% for 11 patients. Data was not available for two patients.
During hospital treatment, 4 patients had discontinued infusions at
least for a period of time, while during home treatment only one patient
incurred in a temporary interruption of infusions, which involved only
one infusion and had no eﬀect on the determination of total com-
pliance.
A total of 4 adverse reactions out of 4269 infusions (0,093%) were
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reported in 2 patients during home treatment. All reactions were con-
sidered related to treatment and not serious, consisting of cutaneous
rash which subsided in all patients spontaneously or after administra-
tion of antihistaminics. No anaphylactic reactions were observed.
4. Discussion
A patient-centric home infusion program has been implemented in
Italy since 2008 for patients with FD treated with agalsidase alfa, in
order to avoid frequent travels and hospital admissions to receiving
periodical IV infusions of ERT.
Our multicentric, observational, longitudinal data analysis on a
large cohort of Italian FD patients and a large number of delivered in-
fusions (4269) in the home therapy setting, showed that ERT admin-
istration at home is safe and that the home infusion program can po-
sitively inﬂuence treatment compliance by reducing the number of
therapy interruptions and improve the adherence to in-label dose-re-
gimen and treatment schedule. In the present study, compliance to
treatment was measured by the patient-reported percentage of lost in-
fusions as reported by Linthorst et al. [23] in a previous experience. As
mentioned, during the home therapy program, compliance reached
100% while during hospital treatment> 20% of patients had a com-
pliance lower than 90%, meaning that at least one infusion out of ten
was lost. As a direct consequence, we can argue that improved com-
pliance to ERT could result, in the long term, in a positive eﬀect on
treatment outcome, as shown by the trend of disease severity as in-
dicated by the MSSI score: while median MSSI score slightly, even if
signiﬁcantly, increased during the timeframe of hospital treatment, it
remained stable after the home therapy treatment start, up to the last
follow up. This was, to our opinion, directly correlated to the amelio-
rated compliance to treatment regimen. In fact, patients who experi-
enced an improvement in disease-related status, as assessed by the MSSI
score, after entering the home infusion program, had previously a
suboptimal adherence while on hospital treatment. However, a longer
duration of hospital treatment compared to home infusion (average:
4 years vs 1 years and 11 months) should be taken into account as it
may have had a role in slightly determining a disease progression in-
dependently from the treatment setting.
The number of adverse events recorded during home treatment, that
were not higher than expected, all of mild intensity and managed at
home without recourse to hospital, clearly demonstrates that home
infusions can be considered at least as safe as infusions administered in
a hospital setting. The home infusion program called Fabry@Home
involves a professional team consisting of a treating physician and a
registered nurse who is dedicated to the infusion of agalsidase alfa. The
nurse is in real-time remote contact with the physician, who is im-
mediately notiﬁed in case of an adverse event that is timely and
properly addressed. In addition, stringent eligibility criteria for patients
entering the home infusion program are observed, including no adverse
events occurred during the last 4 infusions in a hospital setting, thus
providing further safety warranty for patients.
The slight increase in MSSI during the hospital treatment and the
clinical severity of the disease did not preclude the possibility of those
patients to access the Fabry@Home program, including for kidney
transplant patients and pregnant women, ensuring a setting which was
more comfortable but still safe despite patient's clinical conditions.
In addition, patients who joined the home infusion program, ex-
perienced a subjective amelioration of their self-reported health-related
status (QoL). Even if no statistically signiﬁcant changes occurred in EQ-
5 VAS, the minimum value of the score was 60 after home treatment
start compared to 20 during hospital treatment. This result may be a
direct consequence of the improvement or stabilization of self-reported
QoL that 58% of patients experienced following home infusion start,
probably due to the lack of hospitalization related to treatment ad-
ministration.
5. Conclusions
The availability of a home care model, built around patient needs
and his daily habits, may allow an improvement of treatment com-
pliance by reducing the number of treatment interruptions and allowing
a better adherence to treatment dose and schedule for FD. We conclude
that home infusions in eligible patients with FD are safe and contribute
to improve treatment compliance and therapeutic clinical outcomes
and may have a positive impact on self-perceived QoL.
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